DA-1726

July 9, 2026: MetaVia Inc. (NASDAQ: MTVA) reported that all enrolled active patients in Part 3 of its Phase 1 trial of DA-1726 for obesity have completed dose titration and are now at the highest target doses in both cohorts: 48 mg in Part 3A and 64 mg in Part 3B. Part 3 consists of two 16-week titration cohorts evaluating one-step (16 mg for 4 weeks → 48 mg for 12 weeks) versus two-step escalation (16 mg for 4 weeks → 32 mg for 4 weeks → 64 mg for 8 weeks) to optimize tolerability.

The planned enrollment is ~40 obese, otherwise healthy adults (about 20 per part), randomized 4:1 (16 active; 4 placebo). The study assesses safety/tolerability, PK, and PD; primary endpoints include AEs/SAEs/TEAEs and discontinuations, with secondary/exploratory measures including weight, waist circumference, BMI, and metabolic/glycemic/lipid markers.

MetaVia said topline data remain on track for 4Q 2026. The trial is listed as NCT06252220.